Details of the Drug Reposition

General Information of This Drug (ID: DMQTJSX)

Drug Name
Fluvoxamine   DMQTJSX
Synonyms
Dumyrox; Fluvoxamina; Fluvoxaminum; Fluvoxamina [INN-Spanish]; Fluvoxamine (INN); Fluvoxamine [INN:BAN]; Fluvoxamine-CR; Fluvoxaminum [INN-Latin]; Luvox (TN); (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Obsessive compulsive disorder DIS1ZMM2 6B20 Approved [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Social phobia DISQGN78 6B04 Discontinued in Phase 3 [3]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 075893.
2 ClinicalTrials.gov (NCT04342663) A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection. U.S. National Institutes of Health.
3 Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu